Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
NCT01182493 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
Conditions Studied
Interventions
- DEVICE Insulin Pump (Medtronic Minimed Paradigm® VEO)
Study Locations (20)
Other
- City hopital Vienna-Hieting — Vienna
- CHU Côte de Nacre — Caen
- CHU - Ste Marguerite — Marseille
- Hopital Lapeyronie — Montpellier
- CHU de Nancy — Nancy
- CHU Strasbourg — Strasbourg
- CHU Toulouse Rangueil — Toulouse
- Fachklinik Bad Heilbrunn — Bad Heilbrunn
- Zentrum für Diabetes und Gefäßerkrankungen — Münster
Ontario
- LMC Endocrinology Centre — Oakville
- Canadian Centre for Research on Diabetes — Smiths Falls
- Toronto General Hsopital — Toronto
New York
- Albany Medical College — Albany
- SUNY Upstate Medical University — Syracuse
British Columbia
- Endocrinologist, 202-301 Columbia Street East — New Westminster
- 416-1033 Davie St — Vancouver
Georgia
- Atlanta Diabetes Associates — Atlanta
Alberta
- Clinical Professor Department of Medicine University of Calgary — Calgary
Newfoundland and Labrador
- Health Science Centre — St. John's
Quebec
- McGill University, McGill Nutrition and Food Science Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01182493
The ClinicalTrials.gov registry entry for NCT01182493 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Diabetes, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention — of which Insulin Pump (Medtronic Minimed Paradigm® VEO) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01182493 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, Ontario, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01182493 about?
NCT01182493 is a clinical study titled "OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy". The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
What is the current status of trial NCT01182493?
This trial is currently completed. It is a NA study. The enrollment target is 331 participants. The study started on 2010-12. Estimated completion is 2014-08.
What conditions does trial NCT01182493 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01182493?
The interventions under investigation include: Insulin Pump (Medtronic Minimed Paradigm® VEO) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01182493?
This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01182493 being conducted?
This trial has 20 study locations across Georgia, New York, Alberta, British Columbia, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.